AltMountain

Soleus Capital Management, L.P.

Greenwich, CT · CRD 294459
Hedge fund manager

Soleus Capital Management, L.P. is an SEC-registered investment adviser based in Greenwich, CT that reports managing 1 hedge fund on Form ADV. It reports $3.7 billion in regulatory assets under management. Its private funds, of all types, hold $3.8 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +25.8% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +90.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$3.7 billionForm ADV Item 5.F
Gross assets of private funds
$3.8 billionAll private fund types, Form ADV
Hedge funds managed
112 private funds in total
Employees
23Form ADV Item 5.A
Registration
SEC-registered adviserCRD 294459
Latest Form ADV
04/27/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+25.8%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+90.5%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$2.9 billion97 positions, 2026-06-30
$84$137$191Q3 2024Q1 2025Q3 2025Q1 202613F est. $191S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+25.0%+14.8%
Q1 2026+0.6%-4.6%
Q4 2025+43.1%+2.4%
Q3 2025+25.5%+7.8%
Q2 2025-3.8%+10.4%
Q1 2025-11.4%-4.5%
Q4 2024-11.4%+2.1%
Q3 2024+11.6%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 97 share positions ($2,813,021,888) reported by Soleus Capital Management, L.P. on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Krystal Biotech Inc13.47%
  • Insulet Corp8.01%
  • Novocure LTD5.34%
  • TG Therapeutics Inc5.07%
  • United Therapeutics Corp Del4.99%
  • Celcuity Inc4.76%
  • Rigel Pharmaceuticals Inc3.16%
  • Inspire Med SYS Inc2.98%
  • Erasca Inc2.66%
  • Beta Bionics Inc2.53%
StockValue% of 13F portfolioSharesShares vs prior quarter
Krystal Biotech Inc$379,018,63213.47%1,139,700+21.34%
Insulet Corp$225,256,4558.01%1,726,500+64.59%
Novocure LTD$150,341,1275.34%9,425,776-4.92%
TG Therapeutics Inc$142,583,0515.07%2,556,168-12.70%
United Therapeutics Corp Del$140,349,5104.99%259,000+14.81%
Celcuity Inc$133,813,0754.76%1,682,760-1.26%
Rigel Pharmaceuticals Inc$88,764,7183.16%1,843,504Unchanged
Inspire Med SYS Inc$83,705,5902.98%1,206,828-37.52%
Erasca Inc$74,941,9202.66%5,112,000+89.33%
Beta Bionics Inc$71,055,6922.53%3,743,714-14.79%
Ani Pharmaceuticals Inc$70,870,0752.52%975,500+12.42%
Vericel Corp$62,379,9282.22%1,554,059+6.50%
Geron Corp$57,525,4512.04%46,768,659+9.25%
Parabilis Medicines Inc$54,392,8921.93%1,684,512+14.98%
Argenx SE$47,322,2091.68%49,350+147.31%
Axogen Inc$45,315,5201.61%1,081,000+1,795.29%
Neuropace Inc$44,279,6801.57%3,218,000+10.54%
Evolus Inc$40,720,0001.45%5,090,000+518.90%
Zai Lab LTD$40,642,6201.44%1,543,000New
Progyny Inc$39,850,5801.42%1,582,000-1.25%
Trevi Therapeutics Inc$39,061,0511.39%2,727,727+131.24%
Nuvectis Pharma Inc$36,129,0971.28%1,710,658+71.07%
Edap TMS S A$32,672,3651.16%7,309,254Unchanged
Avalyn Pharmaceuticals Inc$29,031,3101.03%1,019,000+143.20%
Kodiak Sciences Inc$27,204,3770.97%286,966New
Silence Therapeutics PLC$26,075,7010.93%2,385,700+278.68%
Inhibikase Therapeutics Inc$23,067,3750.82%11,225,000+3.22%
Arcus Biosciences Inc$22,265,4600.79%862,000-26.25%
Legend Biotech Corp$21,591,5900.77%1,085,550-9.91%
Nurix Therapeutics Inc$21,153,1850.75%892,163-39.11%
Inhibrx Biosciences Inc$21,016,8000.75%210,000New
Adlai Nortye LTD$20,357,6800.72%1,272,355+213.76%
Palisade Bio Inc$20,244,8080.72%14,996,154+14.79%
Alkermes PLC$20,167,0470.72%497,706-51.64%
Tango Therapeutics Inc$20,017,3100.71%802,297+13.16%
Biodesix Inc$19,921,5180.71%667,835+13.97%
Pharvaris N V$19,158,8800.68%604,000-17.36%
Insmed Inc$16,778,5800.60%147,000+62.88%
Praxis Precision Medicines I$16,458,8630.59%56,515-68.16%
Jade Biosciences Inc$16,451,5380.58%1,170,928-24.49%
Kiniksa Pharmaceuticals Intl$16,336,4560.58%218,958-11.12%
Conmed Corp$16,057,2050.57%347,333New
Eton Pharmaceuticals Inc$15,864,1200.56%308,101New
Orthopediatrics Corp$15,816,1090.56%710,198-3.00%
Organogenesis Hldgs Inc$15,482,3030.55%11,300,951+11.44%
Grail Inc$15,203,0200.54%108,500New
MBX Biosciences Inc$15,176,5420.54%258,897-49.76%
Edgewise Therapeutics Inc$13,397,4720.48%329,987-26.81%
Amneal Pharmaceuticals Inc$13,252,1200.47%658,000New
Prelude Therapeutics Inc$13,209,4580.47%3,378,378Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 27 new positions, 27 sold out, 28 increased, 36 reduced and 6 unchanged.

Number of positions (a count, not dollars)

  • New positions27
  • Increased28
  • Unchanged6
  • Reduced36
  • Sold out27

New positions

StockValueShares
Zai Lab LTD$40,642,6201,543,000
Kodiak Sciences Inc$27,204,377286,966
Inhibrx Biosciences Inc$21,016,800210,000
Conmed Corp$16,057,205347,333
Eton Pharmaceuticals Inc$15,864,120308,101
Grail Inc$15,203,020108,500
Amneal Pharmaceuticals Inc$13,252,120658,000
Sanofi SA$11,338,250275,000
Tyra Biosciences Inc$9,732,697445,025
Yarrow Bioscience Inc$9,390,682416,993
Astrazeneca PLC$8,477,17552,500
Revolution Medicines Inc$7,440,47036,249
Castle Biosciences Inc$5,014,598141,137
First Tracks Biotherapeutics$4,979,320140,500
Glaukos Corp$4,195,38325,552
Tcgx Acquisition Corp$2,814,750225,000
Electra Therapeutics Inc$2,812,500250,000
Waystar Hldg Corp$1,267,00050,000
Mannkind Corp$1,170,390300,100
Qiagen NV$875,20020,000

Sold out

StockValue at Jun 30, 2026Shares held then
Globus Med Inc$37,049,527468,922
Supernus Pharmaceuticals$24,185,200520,000
Livanova PLC$20,965,114254,957
Spyre Therapeutics Inc$13,050,660147,000
Alnylam Pharmaceuticals Inc$9,949,04233,050
Immunovant Inc$9,709,560252,000
Nektar Therapeutics$8,960,951128,362
Mirum Pharmaceuticals Inc$8,780,25075,000
Artivion Inc$8,718,360388,000
Enliven Therapeutics Inc$8,408,108165,677
Sionna Therapeutics Inc$7,816,451177,687
Immunic Inc$6,916,500450,000
Merck & Co Inc$6,425,00050,000
Relmada Therapeutics Inc$5,827,374842,106
Structure Therapeutics Inc$5,742,690107,000
Karyopharm Therapeutics Inc$4,298,800440,000
Tectonic Therapeutic Inc$3,495,388101,684
Arrivent Biopharma Inc$1,737,00050,000
Corcept Therapeutics Inc$1,708,82819,653
Veracyte Inc$1,468,25025,000

Largest increases

StockChange in sharesChangeValue nowShares now
Insulet Corp+677,500+64.59%$225,256,4551,726,500
Krystal Biotech Inc+200,446+21.34%$379,018,6321,139,700
Axogen Inc+1,023,964+1,795.29%$45,315,5201,081,000
Erasca Inc+2,412,000+89.33%$74,941,9205,112,000
Evolus Inc+4,267,572+518.90%$40,720,0005,090,000
Argenx SE+29,395+147.31%$47,322,20949,350
Trevi Therapeutics Inc+1,548,109+131.24%$39,061,0512,727,727
Silence Therapeutics PLC+1,755,700+278.68%$26,075,7012,385,700
United Therapeutics Corp Del+33,413+14.81%$140,349,510259,000
Avalyn Pharmaceuticals Inc+600,000+143.20%$29,031,3101,019,000
Nuvectis Pharma Inc+710,658+71.07%$36,129,0971,710,658
Adlai Nortye LTD+866,832+213.76%$20,357,6801,272,355
Ani Pharmaceuticals Inc+107,740+12.42%$70,870,075975,500
Parabilis Medicines Inc+219,442+14.98%$54,392,8921,684,512
Insmed Inc+56,750+62.88%$16,778,580147,000
Iovance Biotherapeutics Inc+401,977+267.98%$8,180,299551,977
Geron Corp+3,960,000+9.25%$57,525,45146,768,659
Neuropace Inc+306,878+10.54%$44,279,6803,218,000
Vericel Corp+94,907+6.50%$62,379,9281,554,059
Palisade Bio Inc+1,932,467+14.79%$20,244,80814,996,154

Largest reductions

StockChange in sharesChangeValue nowShares now
Inspire Med SYS Inc-724,608-37.52%$83,705,5901,206,828
Indivior Pharmaceuticals Inc-1,054,000-99.06%$358,50010,000
Praxis Precision Medicines I-121,002-68.16%$16,458,86356,515
Unitedhealth Group Inc-79,340-99.17%$242,273660
Urogen Pharma LTD-599,536-72.25%$9,356,033230,274
Alkermes PLC-531,546-51.64%$20,167,047497,706
TG Therapeutics Inc-371,727-12.70%$142,583,0512,556,168
Avalo Therapeutics Inc-1,271,384-76.82%$5,880,496383,594
Syndax Pharmaceuticals Inc-1,012,049-62.16%$11,580,612615,990
Biomarin Pharmaceutical Inc-254,452-67.75%$7,267,200121,120
MBX Biosciences Inc-256,382-49.76%$15,176,542258,897
Nurix Therapeutics Inc-573,000-39.11%$21,153,185892,163
Sophia Genetics SA-1,555,000-99.36%$83,80010,000
Beta Bionics Inc-650,000-14.79%$71,055,6923,743,714
Vir Biotechnology Inc-979,029-97.90%$234,45620,971
Belite Bio Inc-49,000-96.98%$258,8061,524
Arcus Biosciences Inc-306,738-26.25%$22,265,460862,000
Novocure LTD-487,625-4.92%$150,341,1279,425,776
Tandem Diabetes Care Inc-475,000-82.61%$1,631,000100,000
Procept Biorobotics Corp-402,642-40.14%$10,938,523600,358

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private equity funds filing Form D (3)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (5)

Fund
Gross assets
Minimum
Owners
Adviser
Soleus Capital Master Fund, L.P.
Cayman IslandsHedge fund
Gross assets$1.6B
Minimum$5.0M
Owners471
AdviserSoleus Capital Management, L.P.
Soleus Private Equity Fund III, L.P.
Delaware, United StatesPrivate equity fund
Gross assets$195M
Minimum$3.0M
Owners108
AdviserSoleus Capital Management, L.P.
Soleus Private Equity Fund II, L.P.
Delaware, United StatesPrivate equity fund
Gross assets$181M
Minimum$3.0M
Owners125
AdviserSoleus Capital Management, L.P.
Soleus Private Equity Fund I, L.P.
Delaware, United StatesPrivate equity fund
Gross assets$25.3M
Minimum$3.0M
Owners59
AdviserSoleus Capital Management, L.P.
Soleus Capital Special Opportunities Fund, L.P.
Delaware, United StatesHedge fund
Gross assets$7.2M
Minimum$1.0M
Owners42
AdviserSoleus Capital Management, L.P.

As reported in the adviser's Form ADV filed Jul 3, 2024. Funds also listed from Form D are shown above.

Fund vehicles: feeder funds and single-deal vehicles (1)

Fund
Gross assets
Minimum
Owners
Adviser
Soleus Bb Spv, LLC
Delaware, United StatesPrivate equity fund
Gross assets$8.5M
Minimum$15K
Owners32
AdviserSoleus Capital Management, L.P.

Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌​⁠